Related Experiment Video

Updated: Dec 20, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.6K

Therapeutic Application of PARP Inhibitors in Neuro-Oncology

Jianfang Ning1, Hiroaki Wakimoto2

  • 1Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.

Trends in Cancer
|February 17, 2020
PubMed

Insights

Poly(ADP-ribose) polymerase 1 inhibitors (PARPis) show promise in treating brain tumors by targeting DNA repair pathways. This review explores their application and challenges in neuro-oncology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerase 1 (PARP1) is crucial for DNA damage repair and genomic stability.
  • PARP inhibitors (PARPis) leverage synthetic lethality in BRCA1/2-mutant cancers, leading to approved therapies.
  • Research is expanding PARPi applications to BRCA wild-type and homologous recombination-proficient cancers, including brain tumors.

Purpose of the Study:

  • To review recent advancements in PARPi therapy for brain tumors.
  • To discuss the current potential and obstacles for using PARPis in neuro-oncology.

Main Methods:

  • Literature review of preclinical and clinical studies on PARPi in brain tumors.
  • Analysis of sensitivity biomarkers and combination strategies for PARPi therapy.
  • Discussion of challenges and opportunities in neuro-oncology.

Main Results:

  • PARPis have demonstrated clinical activity in BRCA-mutant cancers.
  • Biomarkers and combination strategies are being identified to broaden PARPi efficacy.
  • PARPi therapy shows potential in central nervous system malignancies.

Conclusions:

  • PARPi therapy is a developing area in neuro-oncology with significant potential.
  • Further research is needed to overcome challenges and optimize PARPi use in brain tumors.
Keywords:
DNA damage responsePoly(ADP-ribose) polymerase inhibitorcombination therapyhomologous recombination repairneuro-oncology

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.1K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K